About HC2
HC2 Holdings, Inc. is a publicly traded (NYSE MKT:HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. HC2 has a diverse array of operating subsidiaries across seven reportable segments, including Construction, Marine Services, Energy, Telecommunications, Life Sciences, Insurance and Other. HC2’s largest operating subsidiaries include DBM Global Inc., a family of companies providing fully integrated structural and steel construction services, and Global Marine Systems Limited, a leading provider of engineering and underwater services on submarine cables. Founded in 1994, HC2 is headquartered in New York, New York.
Latest News
HC2 Holdings, Inc. Sets First Quarter 2017 Earnings Release Date and Webcast Posted 4/26/2017 4:18:21 PM

NEW YORK, April 26, 2017 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (NYSE MKT:HCHC) (“HC2” or the “Company”) announced today that it will release its financial results for the first quarter 2017 on Wednesday, May 10, 2017 after the market closes.

The Company will host an earnings conference call reviewing these results and its operations the same day, beginning at 5:00 p.m. ET. Participating on the call will be Philip Falcone, the Company’s Chairman, President and CEO, Michael Sena, Chief Financial Officer and Andrew G. Backman, Managing Director of Investor Relations and Public Relations.

Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the Internet and can be accessed by all interested parties through HC2’s website, www.hc2.com in the "Investor Relations" section. To listen to the live call, please go to the "Investor Relations" section of the Company's website at least 15 minutes prior to the start of the call to register and download any necessary audio software. For those who are not able to listen to the live broadcast, a replay will be available shortly after the call on the HC2 website.

Conference Call Details

Live Call
Dial-In (Toll Free): 1-866-395-3893
International Dial-In: 1-678-509-7540
Participant Entry Number: 13442870

Conference Replay*
Domestic Dial-In (Toll Free): 1-855-859-2056
International Dial-In: 1-404-537-3406
Conference Number: 13442870

*Available approximately two hours after the end of the conference call through June 10, 2017.

About HC2

HC2 Holdings, Inc. is a publicly traded (NYSE MKT:HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders.  HC2 has a diverse array of operating subsidiaries across seven reportable segments, including Construction (formerly Manufacturing), Marine Services, Energy (formerly Utilities), Telecommunications, Life Sciences, Insurance and Other.  HC2's largest operating subsidiaries include DBM Global Inc., a family of companies providing fully integrated structural and steel construction services, and Global Marine Systems Limited, a leading provider of engineering and underwater services on submarine cables. Founded in 1994, HC2 is headquartered in New York, New York.  Learn more about HC2 and its portfolio companies at www.hc2.com.

Cautionary Statement Regarding Forward-Looking Statements

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements. Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. The forward-looking statements in this press release include without limitation statements regarding our expectation regarding building shareholder value.  Such statements are based on the beliefs and assumptions of HC2's management and the management of HC2's subsidiaries. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and the Company’s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent reports on Forms 10-K, 10-Q and 8-K. Such important factors include, without limitation, issues related to the restatement of our financial statements; the fact that we have historically identified material weaknesses in our internal control over financial reporting, and any inability to remediate future material weaknesses; capital market conditions; the ability of HC2's subsidiaries to generate sufficient net income and cash flows to make upstream cash distributions; volatility in the trading price of HC2 common stock; the ability of HC2 and its subsidiaries to identify any suitable future acquisition opportunities; our ability to realize efficiencies, cost savings, income and margin improvements, growth, economies of scale and other anticipated benefits of strategic transactions; difficulties related to the integration of financial reporting of acquired or target businesses; difficulties completing pending and future acquisitions and dispositions; effects of litigation, indemnification claims, and other contingent liabilities; changes in regulations and tax laws; and risks that may affect the performance of the operating subsidiaries of HC2. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.

You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to HC2 or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and HC2 undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For information on HC2 Holdings, Inc., please contact:
Andrew G. Backman
Managing Director – Investor Relations & Public Relations
abackman@hc2.com
212-339-5836

Primary Logo

HC2 Holdings, Inc.

Read More
BeneVir Granted Patent Protecting Lead Oncolytic Immunotherapy Stealth-1h and Other Platform Assets Posted 4/25/2017 11:40:00 AM

GAITHERSBURG, MD, April 25, 2017 – BeneVir Biopharm, Inc., a biotechnology company developing oncolytic immunotherapies for the treatment of cancer, announced today that the U.S. Patent and Trademark Office has issued US Patent No. 9,623,059, entitled "Oncolytic Herpes Simplex Virus and Therapeutic Uses Thereof", covering the composition of matter for Stealth-1H, BeneVir's lead oncolytic immunotherapy, as well as other platform assets. BeneVir is a portfolio company within Pansend Life Sciences, a subsidiary of HC2 Holdings, Inc. (NYSE MKT: HCHC)

Oncolytic immunotherapies are live, infectious viruses that selectively replicate in tumors with the goal of stimulating an anti-tumor immune response. Stealth-1H is the first oncolytic immunotherapy resistant to the anti-viral effects of both innate and acquired immunity. This resistance allows Stealth-1H to safely replicate, spread, and kill tumor cells despite a robust, multi-armed immune attack against the virus. While anti-viral immune attack is amplified when oncolyticimmunotherapies are combined with immunostimulatory agents such as anti-PD1/PDL1, OX40L, and ICOS-Ligand, Stealth-1H hides from the immune system, enabling maximum efficacy incombination with these agents.

The patent is exclusively licensed to BeneVir from NYU School of Medicine. The technology originated in the lab of Ian Mohr, Ph.D., Professor of Microbiology at NYU School of Medicine, and Chair of BeneVir's Scientific Advisory Board. Dr. Mohr is a world leader in the field of oncolytic immunotherapy and invented key intellectual property used to create the first FDA-approved oncolytic immunotherapy.

"I am delighted that this patent further strengthens the product development program at BeneVir. I look forward tocontinuing the exciting, productive relationship between BeneVir and mylab," said Dr. Mohr.

"This patent protects BeneVir's product platform through 2032," said Matt Mulvey, BeneVir CEO. "We plan to bring Stealth-1H into the clinic next year and accelerate the pre-clinical development of our platform assets to help a diverse array of patients whose tumors do not respond to current therapeuticoptions, including immune checkpoint inhibitors."

About BeneVir
BeneVir Biopharm, Inc., is a portfolio company within Pansend Life Sciences, a subsidiary of HC2 Holdings, Inc. Its offices and laboratories are located in Gaithersburg, MD, which is part of the BioHealth Capital Region. BeneVir is developing a platform of oncolytic immunotherapies based on T-StealthTM Technology, which promotes the persistence and efficacy of oncolytic immunotherapies in advanced tumors. Learn moreabout BeneVir at http:///www.benevir.com.

About HC2
HC2 Holdings, Inc. is a publicly traded (NYSE MKT:HCHC) diversified holding company, which seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders. HC2 has a diverse array of operating subsidiaries across seven reportable segments, including Construction (formerly Manufacturing), Marine Services, Energy (formerly Utilities), Telecommunications, Life Sciences, Insurance and Other. HC2's largest operating subsidiaries include DBM Global Inc., a family of companies providing fully integrated structural and steel construction services, and Global Marine Systems Limited, a leading provider of engineering and underwater services on submarine cables. Founded in 1994, HC2 is headquartered in New York, New York. Learn more about HC2 and its portfolio companies atwww.hc2.com.

Contact
BeneVir Biopharm, Inc.
Katherine Sacksteder
240-474-5280

HC2 Holdings, Inc.
Andrew Backman
212-339-5836


Read More